ALSO READIPCA Laboratories skids on profit booking Jyothy Laboratories sizzles after bulk deal Board of Neuland Laboratories approves change in CFO Neuland Laboratories standalone net profit declines 75.81% in the June 2017 quarter Neuland Laboratories standalone net profit declines 74.68% in the September 2017 quarter
On the BSE, 9,448 shares were traded on the counter so far as against average daily volumes of 4,230 shares in the past one quarter. The stock had hit a low of Rs 871 so far during the day, which is a 52-week low. The stock hit a high of Rs 945 so far during the day. The stock had hit a record high of Rs 1680.00 on 5 April 2017.
The stock had underperformed the market over the past one month till 5 December 2017, sliding 26.57% compared with the Sensex's 2.62% fall. The stock had also underperformed the market over the past one quarter, declining 28.2% as against the Sensex's 3.12% rise. The scrip had also underperformed the market over the past one year, sliding 14.02% as against the Sensex's 24.49% rise.
The small-cap company has equity capital of Rs 8.88 crore. Face value per share is Rs 10.
Shares of Neuland Laboratories had declined 10.97% in the preceding four trading sessions to settle at Rs 882.10 yesterday, 5 December 2017, from its closing of Rs 990.80 on 29 November 2017.
Neuland Laboratories' net profit fell 74.7% to Rs 2.59 crore on 15.9% decline in net sales to Rs 125.85 crore in Q2 September 2017 over Q2 September 2016.
Neuland Laboratories is engaged in the manufacturing of active pharmaceutical ingredients (APIs).
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)